# Molecular docking approaches in mycetoma: Toward improved patient management

## TL;DR

This paper explores how molecular docking can help develop better treatments for mycetoma, a neglected tropical disease caused by fungal pathogens like Madurella mycetomatis.

## Contribution

The paper highlights molecular docking as a novel computational strategy to identify effective anti-mycetoma agents by targeting key pathogenic proteins and pathways.

## Key findings

- Molecular docking enables rapid virtual screening of compounds against essential M. mycetomatis targets like CYP51 and DHFR.
- Disrupting melanin biosynthesis and metal ion homeostasis could weaken the protective grain and improve drug efficacy.
- Combining docking with AI/ML and in vitro validation can accelerate the discovery of affordable, effective treatments for mycetoma.

## Abstract

Mycetoma is a neglected tropical disease characterised by chronic, granulomatous inflammation of the subcutaneous tissues, often leading to disfigurement, disability, and significant socioeconomic burdens. Caused by a diverse array of bacterial and fungal pathogens, eumycetoma is predominantly driven by Madurella mycetomatis, and current treatment strategies are limited and often ineffective. Conventional antifungal therapies, such as itraconazole, require prolonged administration, frequently combined with surgical interventions, yet cure rates remain suboptimal, and recurrence is common. The formidable protective grain, comprising microbial material, melanin, and host-derived substances, acts as a physical and biochemical barrier, impeding the penetration and efficacy of drugs. Additionally, issues such as toxicity, resistance, and high costs further complicate management, underscoring the urgent need for novel therapeutic strategies. Recent advancements in computational drug discovery, particularly molecular docking, offer promising avenues to accelerate the identification of effective anti-mycetoma agents. Molecular docking simulates the interaction between small molecules and target proteins, enabling rapid virtual screening of large compound libraries, including natural products, existing drugs, and synthetic molecules, against key pathogenic targets. This structure-based approach helps prioritise candidates with high binding affinity, guiding subsequent experimental validation and reducing both time and financial costs associated with traditional drug development. When integrated with artificial intelligence (AI) and machine learning (ML), these methods can enhance predictive accuracy, uncover novel bioactive scaffolds, and facilitate the repurposing of FDA-approved drugs such as montelukast and vilanterol. Key molecular targets in M. mycetomatis include enzymes and pathways critical for pathogen survival and virulence, notably cytochrome P450 (CYP51), dihydrofolate reductase (DHFR), chitin synthase, melanin biosynthesis pathways, and metal ion acquisition systems. Melanin production, via DHN-melanin, DOPA-melanin, and pyomelanin pathways, contributes to grain pigmentation and structural integrity, while metal ions such as iron and zinc are vital for enzymatic activities, grain formation, and fungal virulence. Disrupting metal ion homeostasis through targeting zincophores, siderophores, and zinc-binding proteins represents a promising therapeutic strategy to weaken grain robustness and enhance drug penetration. Despite the potential of molecular docking, limitations such as reliance on homology models, static protein structures, and the absence of cellular context necessitate complementary approaches, including molecular dynamics simulations and in vitro validation. These combined efforts can refine candidate compounds, optimise binding affinities, and predict pharmacokinetic properties. Furthermore, integrating docking results with clinical data and global collaboration platforms can accelerate the discovery of affordable, effective treatments tailored to endemic regions. In conclusion, leveraging molecular docking and computational methods to target essential M. mycetomatis pathways offers a promising frontier in mycetoma research. By identifying novel inhibitors and understanding pathogen biology at a molecular level, these approaches can inform targeted therapies, reduce treatment durations, and improve patient outcomes. Future research should focus on validating computational predictions experimentally and translating these findings into clinical practice, with an emphasis on accessible, cost-effective interventions for vulnerable populations affected by this neglected disease.